Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31597661 | 0.89 | PTPN1 (0.54) | PTPN1CASP3CTSBCTSKGRB2 | |
| SCHEMBL29872083 | 0.85 | PTPN1 (0.60) | PTPN1GRB2TLR2 | |
| SCHEMBL24221105 | 0.84 | PTPN1 (0.60) | PTPN1GRB2 | |
| SCHEMBL29355030 | 0.84 | PTPN1 (0.60) | PTPN1GRB2 | |
| SCHEMBL29417902 | 0.84 | CASP3 (0.62) | PTPN1CASP3CTSBCTSK | |
| SCHEMBL30718910 | 0.84 | TLR2 (0.49) | PTPN1CASP3TLR2 | |
| SCHEMBL15593373 | 0.81 | TLR2 (0.51) | PTPN1CASP3TLR2 | |
| SCHEMBL29706214 | 0.81 | TLR2 (0.51) | PTPN1CASP3TLR2 | |
| SCHEMBL29380298 | 0.81 | KMT2A (0.49) | PTPN1CASP3TLR2 | |
| SCHEMBL30771372 | 0.81 | PTPN1 (0.58) | PTPN1CASP3GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | PTPN1 484/4885CASP3 424/4885CTSB 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.